6 Works

Additional file 1 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 1: Supplementary Figure 1. Flow diagram of patients included in the analysis set from GeparTrio study.

Additional file 1 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 1: Supplementary Figure 1. Flow diagram of patients included in the analysis set from GeparTrio study.

Additional file 2 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 2: Supplementary Figure 2. Distribution of EVI1 continuous expression in breast cancer: A: Histogram of EVI1 continuous expression in the entire cohort (N=993); B: Boxplots of EVI1 continuous expression within breast cancer subtypes. Note, 882/993 patients with available BC subtype information were included in this analysis. Horizontal bold lines present EVI1 median values of 116.65 in HR+/HER2-, 98.67 in HR+/HER2+, 114.77in HR-/HER2+, and 115.64 in TNBC; boxes present the interquartile range between first...

Additional file 3 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 3: Supplementary Figure 3. Kaplan-Meier estimates of DFS (A) and OS (B) according to EVI1 expression in the non-pCR subgroup. Abbreviations:pCR, pathological complete response; DFS, disease-free survival; OS, overallsurvival.

Additional file 2 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 2: Supplementary Figure 2. Distribution of EVI1 continuous expression in breast cancer: A: Histogram of EVI1 continuous expression in the entire cohort (N=993); B: Boxplots of EVI1 continuous expression within breast cancer subtypes. Note, 882/993 patients with available BC subtype information were included in this analysis. Horizontal bold lines present EVI1 median values of 116.65 in HR+/HER2-, 98.67 in HR+/HER2+, 114.77in HR-/HER2+, and 115.64 in TNBC; boxes present the interquartile range between first...

Additional file 3 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 3: Supplementary Figure 3. Kaplan-Meier estimates of DFS (A) and OS (B) according to EVI1 expression in the non-pCR subgroup. Abbreviations:pCR, pathological complete response; DFS, disease-free survival; OS, overallsurvival.

Registration Year

  • 2022
    6

Resource Types

  • Audiovisual
    6

Affiliations

  • Charité - University Medicine Berlin
    6
  • Universitätsklinikum Erlangen
    6
  • University Hospital Heidelberg
    6
  • Sankt Gertrauden Krankenhaus
    6
  • Philipps University of Marburg
    6
  • University Hospital Schleswig-Holstein
    6
  • University Medical Center Hamburg-Eppendorf
    6
  • Universitätsklinikum Aachen
    6
  • LMU Klinikum
    6
  • Universitätsklinikum Gießen und Marburg
    6